Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Athenex Inc (ATNX)

Athenex Inc (ATNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 134,985
  • Shares Outstanding, K 121,608
  • Annual Sales, $ 120,180 K
  • Annual Income, $ -199,770 K
  • 60-Month Beta 1.09
  • Price/Sales 1.11
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ATNX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.09
  • Most Recent Earnings -0.23 on 07/28/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 727.00% ( +353.93%)
  • Historical Volatility 260.49%
  • IV Percentile 92%
  • IV Rank 61.30%
  • IV High 1,149.89% on 04/27/22
  • IV Low 57.10% on 08/18/21
  • Put/Call Vol Ratio 1.07
  • Today's Volume 1,016
  • Volume Avg (30-Day) 175
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 3,196
  • Open Int (30-Day) 1,959

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.16
  • Number of Estimates 1
  • High Estimate -0.16
  • Low Estimate -0.16
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +51.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4761 +12.98%
on 07/12/22
1.1900 -54.80%
on 08/09/22
+0.0305 (+6.01%)
since 07/11/22
3-Month
0.4051 +32.78%
on 06/30/22
1.1900 -54.80%
on 08/09/22
+0.0403 (+8.10%)
since 05/11/22
52-Week
0.4051 +32.78%
on 06/30/22
3.9100 -86.24%
on 09/02/21
-2.9521 (-84.59%)
since 08/11/21

Most Recent Stories

More News
Athenex, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants

BUFFALO, N.Y., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (“Athenex”) (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery,...

ATNX : 0.5379 (-51.54%)
Athenex (ATNX) Reports Q2 Loss, Lags Revenue Estimates

Athenex (ATNX) delivered earnings and revenue surprises of -76.92% and 6.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ATNX : 0.5379 (-51.54%)
FULC : 7.57 (-2.45%)
Athenex Provides Second Quarter 2022 Financial Results and Business Update

Reports 2Q product sales of $25.8 million, up 26% year-over-yearRaised $85 million in total transaction value in 2Q for total of $125 million in proceeds...

ATNX : 0.5379 (-51.54%)
Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of Clinical Oncology

BUFFALO, N.Y., July 25, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery,...

ATNX : 0.5379 (-51.54%)
Athenex to Provide Corporate and Financial Update for the Second Quarter 2022 on July 28, 2022

BUFFALO, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and...

ATNX : 0.5379 (-51.54%)
Athenex Announces Entry into Agreement to Sell its China API Business to TiHe Capital (Bejing) Co., Ltd.

Expected sale proceeds of approximately $19.0 millionCompany continues to monetize non-core assets to extend cash runwayProceeds from the deal will be used...

ATNX : 0.5379 (-51.54%)
Athenex to Participate in Truist Securities Cell Therapy Symposium

BUFFALO, N.Y., June 23, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and...

ATNX : 0.5379 (-51.54%)
Athenex Announces Sale of Revenues from U.S. and European Royalty and Milestone Interests in Klisyri® (tirbanibulin) to Sagard Healthcare Partners and Oaktree

Company executes on strategy to extend cash runway by monetizing non-core assets Total transaction value of $85 million; at least $80 million to be used...

ATNX : 0.5379 (-51.54%)
Athenex Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy

BUFFALO, N.Y., June 08, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery,...

ATNX : 0.5379 (-51.54%)
Athenex (ATNX) Reports Q1 Loss, Tops Revenue Estimates

Athenex (ATNX) delivered earnings and revenue surprises of -50% and 16.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ATNX : 0.5379 (-51.54%)
KALA : 0.3280 (-5.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Athenex, Inc. is a clinical stage biopharmaceutical company. It engaged in the discovery and development of drugs for the treatment of cancer. The company's platform including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. It operates primarily in Buffalo and...

See More

Key Turning Points

3rd Resistance Point 0.6983
2nd Resistance Point 0.6587
1st Resistance Point 0.5983
Last Price 0.5379
1st Support Level 0.4983
2nd Support Level 0.4587
3rd Support Level 0.3983

See More

52-Week High 3.9100
Fibonacci 61.8% 2.5711
Fibonacci 50% 2.1576
Fibonacci 38.2% 1.7440
Last Price 0.5379
52-Week Low 0.4051

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar